IFNG and influenza: In a pivotal phase III trial (NCT04120194) in older adults (≥65 years), a recombinant quadrivalent nanoparticle influenza vaccine with Matrix-M, called NanoFluTM, has been shown to induce non-inferior immunogenicity in terms of HAI response and a significant greater induction of cellular immunity in comparison with a classic quadrivalent vaccine (Fluzone quadrivalent) seven days after vaccination as measured by ICS (IL-2, CD40L, IFN-γ and TNFα).